A systematic review and meta-analysis of the efficacy and safety of injectable pazufloxacin
Abstract
Background. In October 2024, a new antibiotic, pazufloxacin, was registered in Russia. Information on the efficacy and safety of injectable pazufloxacin is lacking in the Russian literature. Objective. To conduct a systematic literature review and meta-analysis of data on the efficacy and safety of pazufloxacin, an infusion solution. Methods. This review included clinical trials (CTs) evaluating the efficacy and safety of injectable pazufloxacin, conducted in adult volunteers, considering the clinical conditions for which the drug is indicated in the Russian Federation. A meta-analysis was performed based on published results of randomized clinical trials (RCTs) conducted in adult patients with urinary tract infections (UTIs). Results. Of the 1,068 articles identified, 10 were included in this review. Four studies were RCTs, and the remaining studies were before-and-after studies. The efficacy of pazufloxacin varied depending on the site, type of infection, and dose, ranging from 78.7 % to 100 % for UTIs, 75.1 % to 100 % for respiratory tract infections, and 80.0 % to 95.2 % for obstetric and gynecological infections. Despite a trend toward higher efficacy values for pazufloxacin in RCTs, a meta-analysis confirmed the absence of significant differences in efficacy between the compared groups. Notably, 15 years or more have elapsed since most studies were conducted. Given the increasing antibiotic resistance of infectious agents over time, the efficacy of drugs in the Russian…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.